On January 27, 2020, Quench Bio, Inc. closed the transaction. The company has amended the terms of the transaction. The company now received $50,000,000 in its series A round of funding led by new investor RA Capital Management, LLC and included participation from new investor AbbVie Ventures, Inc., and returning investors Atlas Venture L.P., Arix Bioscience plc (LSE:ARIX). Josh Resnick of RA Capital Management, LLC and Adam Houghton of AbbVie Ventures, Inc., will join the board of the company. Additionally, John Cassidy of Arix Bioscience plc will continue his role as Board Observer.